麻豆区

American Society of Addiciton Medicine

Home Publications The ASAM Weekly

  • New Guideline on Benzodiazepine Tapering

    This guideline was developed to help clinicians determine when the risks of continued BZD prescribing outweigh the benefits for a given patient and how to safely taper the medication when indicated. Existing guidelines generally recommend limiting duration of BZD use to 2-4 weeks (except for limited conditions such as severe treatment-resistant generalized anxiety disorder, complex seizure disorders, spasticity, and sleep disorders involving abnormal movements). However, long-term BZD prescribing remains prevalent.
    Full story

Recent and Past Issues

This Week in Addiction Medicine Podcast

A weekly audio summary and podcast of the ASAM Weekly

The ASAM Weekly

Editors & Staff

Editor-in-Chief: Nicholas Athanasiou, MD, MBA, DFASAM
Emeritus Editor: William Haning, MD, DFAPA, DFASAM
Publications Chair: Nicholas Athanasiou, MD, MBA, DFASAM
Co-Editors: Brandon Aden, MD, Jack Woodside, MD, John A. Fromson, MD

Please direct customer service inquiries and comments to: ASAMWeekly@ASAM.org

The ASAM Weekly

Advertiser Services & Sales

Ad space is limited and available on a first-paid, first-published basis. To assure your ad will run in the specific issue you select, Insertion Orders must be signed by an authorized person in your organization and accepted by your customer service representative before taking the advertising units out of the active sales inventory. Payment must be received prior to the run date for an ad. Insertion Orders provide several options for payment in full including all major credit cards or check. Pre-approved billing must be arranged directly by an ASAM representative.

To learn more about advertising opportunities
Contact: Claire Rasmussen <crasmussen@asam.org>